Cosmos HealthCOSM +1.63%29 3-Year ROIIC % is -79.42 as of Dec. 2025. GuruFocus rates COSM with a GF Score™ of 29/100 and a GF Value™ of $0.36 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 113 Medical Distribution companies, Cosmos Health ranks worse than 90.27% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Cosmos Health's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was -79.42%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Cosmos Health's 3-Year ROIIC % or its related term are showing as below:
COSM's 3-Year ROIIC % is ranked worse than 90.27% of 113
companies
in the Medical Distribution industry
Industry Median: 2.2
vs COSM: -79.42
Cosmos Health (NAS:COSM) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Cosmos Health 3-Year ROIIC % Related Terms
Cosmos Health 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Cosmos Health's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Cosmos Health's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cosmos Health 3-Year ROIIC % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Cosmos Health's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Cosmos Health's 3-Year ROIIC % falls into.
Cosmos Health's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -16.541 (Dec. 2025) - -7.474 (Dec. 2022) )
/
( 47.949 (Dec. 2025) - 36.532 (Dec. 2022) )
=
-9.067
/
11.417
=
-79.42%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Cosmos Health (COSM) has a 3-Year ROIIC % of -79.42 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Cosmos Health and its competitors. According to the industry distribution chart, Cosmos Health ranks #102 out of 113 companies in the Medical Distribution industry, placing it in the top 90.3%.
Is Cosmos Health's 3-Year ROIIC % too high?
Cosmos Health's current 3-Year ROIIC % is -79.42. Based on the distribution chart, Cosmos Health ranks #102 out of 113 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Cosmos Health has a GF Score™ of 29/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cosmos Health's 3-Year ROIIC % compare to HKPD and SNYR?
According to the Medical Distribution industry distribution chart, Cosmos Health ranks #102 out of 113 companies for 3-Year ROIIC %. This places Cosmos Health in the lower half of its industry. The industry median 3-Year ROIIC % is 2.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Medical Distribution company?
The median 3-Year ROIIC % among Medical Distribution companies is 2.20, based on 113 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Cosmos Health and its competitors. For the Medical Distribution industry, the median 3-Year ROIIC % is 2.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cosmos Health's current 3-Year ROIIC % is -79.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cosmos Health stock overvalued right now?
Based on GuruFocus' analysis, Cosmos Health (COSM) is currently considered Possible Value Trap. The stock's GF Value™ is $0.36, compared to a current price of $0.17 — trading 51.6% below its estimated fair value. The current 3-Year ROIIC % is -79.42. Cosmos Health's overall GF Score™ is 29/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Cosmos Health (COSM), the current 3-Year ROIIC % is -79.42 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cosmos Health (COSM) Overvalued in 2026?
Based on GuruFocus' analysis, Cosmos Health stock appears to be undervalued.
The current stock price of $0.17 is trading 51.6% below its estimated GF Value™ of $0.36.
GuruFocus considers Cosmos Health to be Possible Value Trap.
Key valuation signals for COSM:
3-Year ROIIC %: -79.42
GF Value™: $0.36 vs. price of $0.17 (51.6% below fair value)
No single metric tells the full story. See the COSM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cosmos Health Inc is a diversified, vertically integrated healthcare group, owner of proprietary pharmaceutical and nutraceutical brands, generics, manufacturer and distributor of healthcare products, engaged in research & development of medicines and repurposing drugs as well as operator of a telehealth platform. The company has developed its own proprietary branded nutraceutical products, named 'Sky Premium Life' and 'Mediterranation'. Its product portfolio includes generics and over-the-counter pharmaceutical products, medicines, as well as nutraceuticals and biocides. The company's Reportable segments are Wholesale, Pharma manufacturing, and Nutraceutical and pharmaceuticals, with the majority of revenue generated from the Wholesale segment.
29GF Score
Get the complete analysis for COSM
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
COSM has been successfully added to your 
